Loading...

We've got a brand new version of Simply Wall St! Try it out

Mycenax Biotech

GTSM:4726
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4726
GTSM
NT$3B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian cells and microbials in Taiwan. The last earnings update was 89 days ago. More info.


Add to Portfolio Compare Print
4726 Share Price and Events
7 Day Returns
-2.8%
GTSM:4726
-1%
TW Biotechs
1.4%
TW Market
1 Year Returns
9.9%
GTSM:4726
-9.6%
TW Biotechs
17.7%
TW Market
4726 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mycenax Biotech (4726) -2.8% 0.5% 1% 9.9% -34.9% -50.8%
TW Biotechs -1% -2.6% -4.5% -9.6% -39.9% -41.4%
TW Market 1.4% 6% 9.8% 17.7% 27.6% 27.7%
1 Year Return vs Industry and Market
  • 4726 outperformed the Biotechs industry which returned -9.6% over the past year.
  • 4726 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
4726
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Mycenax Biotech's competitors could be found in our database.

4726 Value

 Is Mycenax Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Mycenax Biotech. This is due to cash flow or dividend data being unavailable. The share price is NT$21.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mycenax Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mycenax Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:4726 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in TWD NT$-1.98
GTSM:4726 Share Price ** GTSM (2019-11-11) in TWD NT$21.1
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 41.22x
Taiwan, Province of China Market PE Ratio Median Figure of 1,438 Publicly-Listed Companies 16.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mycenax Biotech.

GTSM:4726 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:4726 Share Price ÷ EPS (both in TWD)

= 21.1 ÷ -1.98

-10.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mycenax Biotech is loss making, we can't compare its value to the TW Biotechs industry average.
  • Mycenax Biotech is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does Mycenax Biotech's expected growth come at a high price?
Raw Data
GTSM:4726 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Asia Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.61x
Taiwan, Province of China Market PEG Ratio Median Figure of 244 Publicly-Listed Companies 1.14x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mycenax Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mycenax Biotech's assets?
Raw Data
GTSM:4726 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in TWD NT$9.78
GTSM:4726 Share Price * GTSM (2019-11-11) in TWD NT$21.1
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.4x
Taiwan, Province of China Market PB Ratio Median Figure of 1,939 Publicly-Listed Companies 1.46x
GTSM:4726 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:4726 Share Price ÷ Book Value per Share (both in TWD)

= 21.1 ÷ 9.78

2.16x

* Primary Listing of Mycenax Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mycenax Biotech is good value based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess Mycenax Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Mycenax Biotech has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4726 Future Performance

 How is Mycenax Biotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Mycenax Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
65.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mycenax Biotech expected to grow at an attractive rate?
  • Unable to compare Mycenax Biotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Mycenax Biotech's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare Mycenax Biotech's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:4726 Future Growth Rates Data Sources
Data Point Source Value (per year)
Taiwan, Province of China Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 65.2%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 60.6%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.3%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:4726 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:4726 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-06-30 327 -150 -231
2019-03-31 260 -191 -256
2018-12-31 211 -180 -274
2018-09-30 218 -121 -296
2018-06-30 285 -96 -219
2018-03-31 311 -55 -186
2017-12-31 319 -46 -188
2017-09-30 299 -53 -96
2017-06-30 260 -111 -142
2017-03-31 216 -137 -171
2016-12-31 201 -158 -158
2016-09-30 185 -152 -153

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Mycenax Biotech is high growth as no earnings estimate data is available.
  • Unable to determine if Mycenax Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:4726 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Mycenax Biotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4726 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-06-30 -1.98
2019-03-31 -2.28
2018-12-31 -2.50
2018-09-30 -2.70
2018-06-30 -1.99
2018-03-31 -1.69
2017-12-31 -1.71
2017-09-30 -0.88
2017-06-30 -1.29
2017-03-31 -1.56
2016-12-31 -1.45
2016-09-30 -1.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mycenax Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Mycenax Biotech's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Mycenax Biotech's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Mycenax Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mycenax Biotech has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4726 Past Performance

  How has Mycenax Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mycenax Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mycenax Biotech does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Mycenax Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mycenax Biotech's 1-year growth to the TW Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Mycenax Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mycenax Biotech Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4726 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 326.85 -231.06 72.24 301.10
2019-03-31 260.36 -256.34 61.12 311.11
2018-12-31 211.42 -274.43 60.54 276.09
2018-09-30 218.09 -296.45 63.75 226.53
2018-06-30 285.27 -218.54 62.23 215.71
2018-03-31 310.85 -185.86 64.92 190.21
2017-12-31 318.64 -188.37 65.81 195.47
2017-09-30 298.96 -96.11 59.32 190.80
2017-06-30 259.84 -141.57 50.18 213.83
2017-03-31 215.87 -171.34 44.68 216.81
2016-12-31 200.61 -158.49 40.88 217.78
2016-09-30 184.91 -152.59 36.38 195.76
2016-06-30 155.14 -133.41 33.25 170.44
2016-03-31 132.84 -133.72 35.41 153.61
2015-12-31 134.86 -110.89 33.45 144.97
2015-09-30 129.58 -90.81 32.57 144.43
2015-06-30 84.19 -125.85 34.02 142.63
2015-03-31 120.36 -79.97 28.81 147.79
2014-12-31 113.08 -87.12 28.36 149.11
2014-09-30 98.73 -100.23 30.30 138.72
2014-06-30 97.26 -90.42 28.82 131.43
2014-03-31 67.54 -100.37 30.20 116.15
2013-12-31 63.95 -88.63 29.53 103.33
2013-09-30 48.71 -88.24 30.33 100.74
2013-06-30 43.93 -99.40 29.97 106.08
2013-03-31 32.06 -120.01 27.21 116.85
2012-12-31 35.70 -100.40 26.25 114.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mycenax Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mycenax Biotech has efficiently used its assets last year compared to the TW Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mycenax Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mycenax Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mycenax Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4726 Health

 How is Mycenax Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mycenax Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mycenax Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mycenax Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Mycenax Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 6.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mycenax Biotech Company Filings, last reported 4 months ago.

GTSM:4726 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 1,250.98 105.19 458.24
2019-03-31 1,239.35 107.30 598.26
2018-12-31 907.02 0.00 283.14
2018-09-30 1,007.00 0.00 375.07
2018-06-30 1,047.79 0.00 444.30
2018-03-31 1,106.74 0.00 525.43
2017-12-31 1,143.87 0.00 625.65
2017-09-30 1,255.99 0.00 628.76
2017-06-30 1,232.01 0.00 651.23
2017-03-31 1,249.72 0.00 559.21
2016-12-31 1,316.14 0.00 765.17
2016-09-30 1,333.24 0.00 825.49
2016-06-30 1,351.02 0.00 917.22
2016-03-31 1,396.89 0.00 1,068.83
2015-12-31 1,454.21 0.00 1,165.49
2015-09-30 1,467.51 0.00 1,177.66
2015-06-30 1,519.88 0.00 1,241.96
2015-03-31 1,601.61 0.00 1,326.33
2014-12-31 1,637.11 0.00 1,394.60
2014-09-30 1,632.17 0.00 1,423.33
2014-06-30 1,667.92 0.00 1,447.47
2014-03-31 1,663.27 0.00 1,481.49
2013-12-31 1,705.96 0.00 1,585.61
2013-09-30 872.32 0.00 746.63
2013-06-30 900.16 0.00 787.37
2013-03-31 915.66 0.00 804.97
2012-12-31 179.56 0.00 74.18
  • Mycenax Biotech's level of debt (8.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Mycenax Biotech's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mycenax Biotech has sufficient cash runway for 1.3 years based on current free cash flow.
  • Mycenax Biotech has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 2.8% each year.
X
Financial health checks
We assess Mycenax Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mycenax Biotech has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4726 Dividends

 What is Mycenax Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mycenax Biotech dividends.
If you bought NT$2,000 of Mycenax Biotech shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mycenax Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mycenax Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:4726 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1337 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mycenax Biotech has not reported any payouts.
  • Unable to verify if Mycenax Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mycenax Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mycenax Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Mycenax Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mycenax Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mycenax Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4726 Management

 What is the CEO of Mycenax Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Hwang
CEO Bio

Michael Hwang serves as Chief Executive Officer at Mycenax Biotech Inc.

CEO Compensation
  • Insufficient data for Michael to compare compensation growth.
  • Insufficient data for Michael to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team

Michael Hwang

TITLE
Chief Executive Officer

Jiong Xiang Chen

TITLE
Manager of Finance and Accounting Department

Jin Lian Chen

TITLE
Head of Audit
Board of Directors

Ronjin Lin

TITLE
Chairman

Yi Xu Huang

TITLE
Vice Chairman

Zhao Lian Huang

TITLE
Director

Guo Lan Wen

TITLE
Director

Shang Ding Lu

TITLE
Director

Sun Sheng Zhao

TITLE
Independent Director

Jian Xian Li

TITLE
Independent Director

Shi Lan Yang

TITLE
Supervisor
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Mycenax Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mycenax Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4726 News

Simply Wall St News

4726 Company Info

Description

Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian cells and microbials in Taiwan. The company’s product pipeline includes Trastuzumab for the treatment of HER2-positive metastatic breast cancer and HER2 positive metastatic gastric cancer; Adalimumab for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis; and Omalizumab, a humanized monoclonal antibody IgG1, which is used for allergic asthma and chronic idiopathic urticarial. Its products also comprise GranNEX, a filgrastim that is used for neutropenia, as the adjunct therapy for cancer chemotherapy and AIDS therapy; and AiNEX, a bevacizumab, which is used for metastatic colorectal cancer, non-small cell lung cancer, metastatic breast cancer, glioblastoma, metastatic renal cancer, ovarian cancer, and metastatic cervical cancer. In addition, the company offers LusiNEX, a tocilizumab, which is in Phase I clinical trial used for the treatment of RA, polyarticular idioathic juvenile arthritis, systemic juvenile idiopathic arthritis, and castleman’s disease; and TuNEX, an opinercept, which is in a phase III clinical trial used for the treatment of RA, joint deformities, PsA, ankylosing spondylitis, plaque psoriasis. Further, it provides product development consultation, process development and scale-up, cGMP manufacturing, and cGMP aseptic filling/lyophilization services, as well as drug substance and product manufacturing, and analytical method development services. The company was founded in 2001 and is headquartered in Miaoli County, Taiwan.

Details
Name: Mycenax Biotech Inc.
4726
Exchange: GTSM
Founded: 2001
NT$2,699,850,500
127,955,000
Website: http://www.mycenax.com.tw
Address: Mycenax Biotech Inc.
No.50-7, Keyan Road,
4th Floor,
Miaoli County,
35053,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 4726 Common Stock Taipei Exchange TW TWD 31. Oct 2008
Number of employees
Current staff
Staff numbers
160
Mycenax Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/11 14:56
End of day share price update: 2019/11/11 00:00
Last earnings filing: 2019/08/14
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.